Piper Jaffray analyst Tyler Van Buren notes BeiGene has announced that tislelizumab was approved in China for relapsed/refractory classical Hodgkin's lymphoma, which comes just before year-end and will allow BeiGene to submit for NRDL reimbursement inclusion by the end of 2020. The analyst models cHL sales for tislelizumab in China surpassing $100M by the late 2020s, but believes that the bladder cancer indication could be several-fold larger. Van Buren is encouraged by the approval as some had thought that it was taking too long, but keeps a Neutral rating and a $165 price target on the shares given the recent ASPEN trial miss.